{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T15:14:25Z","timestamp":1794064465477,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1194970"],"award-info":[{"award-number":["APP1194970"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["178140"],"award-info":[{"award-number":["178140"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009717","name":"Eastern Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["707213"],"award-info":[{"award-number":["707213"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["707213"],"award-info":[{"award-number":["707213"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["CA62924, CA009071, GM136577 and CA06973"],"award-info":[{"award-number":["CA62924, CA009071, GM136577 and CA06973"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006352","name":"Virginia and D.K. Ludwig Fund for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000910","name":"Conrad N. Hilton Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000910","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012212","name":"Billi and Bernie Marcus Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012212","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41591-025-04030-w","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:02:22Z","timestamp":1760968942000},"page":"4291-4300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9244-2057","authenticated-orcid":false,"given":"Jeanne","family":"Tie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8189-2132","authenticated-orcid":false,"given":"Jonathan M.","family":"Loree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4926-5689","authenticated-orcid":false,"given":"Rachel","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall C.","family":"Tebbutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Burge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-820X","authenticated-orcid":false,"given":"James","family":"Lynam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0947-9834","authenticated-orcid":false,"given":"Belinda","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Breadner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlyse","family":"Debrincat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6916-8424","authenticated-orcid":false,"given":"Siavash","family":"Foroughi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-0208","authenticated-orcid":false,"given":"Lorraine","family":"Chantrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie H.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-3617","authenticated-orcid":false,"given":"Sharlene","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Ptak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Silliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Dobbyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Popoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-7123","authenticated-orcid":false,"given":"Chetan","family":"Bettegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7135-7451","authenticated-orcid":false,"given":"Nicholas","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5591-1176","authenticated-orcid":false,"given":"Kenneth W.","family":"Kinzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-3854","authenticated-orcid":false,"given":"Bert","family":"Vogelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"AGITG DYNAMIC-III Study Group (Intergroup Study of the Australasian Gastro-Intestinal Trials Group and Canadian Cancer Trials Group)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Australasia Gastro-Intestinal Trials Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue-Anne","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Lundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zee Wan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Saqib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Steel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Aghmesheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Begbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aflah","family":"Roohullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Beale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weng","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Diakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratnesh","family":"Srivastav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deme","family":"Karikios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Underhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirooz","family":"Poursoltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Karki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Karapetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Wuttke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan","family":"Karanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jeffery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Canadian Cancer Trials Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Yelamanchili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl","family":"Roitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Gotfrit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqbal","family":"Mussawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaqil","family":"Kassam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rask","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Hubay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setareh","family":"Samimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Zurawska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Sideris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McGhie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroosh","family":"Arif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Babak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Burkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"4030_CR1","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey, A. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N. Engl. J. Med. 378, 1177\u20131188 (2018).","journal-title":"N. Engl. J. Med."},{"key":"4030_CR2","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1200\/JCO.2013.49.6638","volume":"31","author":"NJ McCleary","year":"2013","unstructured":"McCleary, N. J. et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II\/III colon cancer: findings from the ACCENT database. J. Clin. Oncol. 31, 2600\u20132606 (2013).","journal-title":"J. Clin. Oncol."},{"key":"4030_CR3","doi-asserted-by":"publisher","first-page":"e2525660","DOI":"10.1001\/jamanetworkopen.2025.25660","volume":"8","author":"JW Bong","year":"2025","unstructured":"Bong, J. W., Lee, H., Jeong, S. & Kang, S. Older age threshold for oxaliplatin benefit in stage II to III colorectal cancer. JAMA Netw. Open 8, e2525660 (2025).","journal-title":"JAMA Netw. Open"},{"key":"4030_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2020.07.031","volume":"138","author":"AF Sobrero","year":"2020","unstructured":"Sobrero, A. F. et al. A new prognostic and predictive tool for shared decision making in stage III colon cancer. Eur. J. Cancer 138, 182\u2013188 (2020).","journal-title":"Eur. J. Cancer"},{"key":"4030_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie, J. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra392 (2016).","journal-title":"Sci. Transl. Med."},{"key":"4030_CR6","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","volume":"5","author":"J Tie","year":"2019","unstructured":"Tie, J. et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 5, 1710\u20131717 (2019).","journal-title":"JAMA Oncol."},{"key":"4030_CR7","doi-asserted-by":"publisher","first-page":"e1003620","DOI":"10.1371\/journal.pmed.1003620","volume":"18","author":"J Tie","year":"2021","unstructured":"Tie, J. et al. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: a prospective cohort study. PLoS Med. 18, e1003620 (2021).","journal-title":"PLoS Med."},{"key":"4030_CR8","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura, Y. et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat. Med. 30, 3272\u20133283 (2024).","journal-title":"Nat. Med."},{"key":"4030_CR9","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1158\/1078-0432.CCR-24-0226","volume":"30","author":"S Slater","year":"2024","unstructured":"Slater, S. et al. Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B study. Clin. Cancer Res. 30, 3459\u20133469 (2024).","journal-title":"Clin. Cancer Res."},{"key":"4030_CR10","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.24.00648","volume":"43","author":"J Taieb","year":"2025","unstructured":"Taieb, J. et al. Combined analyses of circulating tumor DNA and Immunoscore in patients with stage III colon cancer: a post hoc analysis of the PRODIGE-GERCOR IDEA-France\/HORG-IDEA-Greece trials. J. Clin. Oncol. 43, 1564\u20131577 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4030_CR11","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"4030_CR12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat. Med. 31, 1509\u20131518 (2025).","journal-title":"Nat. Med."},{"key":"4030_CR13","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/ije\/dyy013","volume":"47","author":"V Gebski","year":"2018","unstructured":"Gebski, V., Gar\u00e8s, V., Gibbs, E. & Byth, K. Data maturity and follow-up in time-to-event analyses. Int. J. Epidemiol. 47, 850\u2013859 (2018).","journal-title":"Int. J. Epidemiol."},{"key":"4030_CR14","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1200\/JCO.2004.09.059","volume":"22","author":"S Gill","year":"2004","unstructured":"Gill, S. et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol. 22, 1797\u20131806 (2004).","journal-title":"J. Clin. Oncol."},{"key":"4030_CR15","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261\u20132272 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4030_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf2341","volume":"383","author":"C Martin-Alonso","year":"2024","unstructured":"Martin-Alonso, C. et al. Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies. Science 383, eadf2341 (2024).","journal-title":"Science"},{"key":"4030_CR17","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1200\/JCO.2007.11.2144","volume":"25","author":"LB Saltz","year":"2007","unstructured":"Saltz, L. B. et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol. 25, 3456\u20133461 (2007).","journal-title":"J. Clin. Oncol."},{"key":"4030_CR18","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1200\/JCO.2008.21.6663","volume":"27","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E. et al. Randomized phase III trial comparing biweekly infusional fluorouracil\/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27, 3117\u20133125 (2009).","journal-title":"J. Clin. Oncol."},{"key":"4030_CR19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/annonc\/mdn680","volume":"20","author":"M Ychou","year":"2009","unstructured":"Ychou, M. et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02\/FFCD9802). Ann. Oncol. 20, 674\u2013680 (2009).","journal-title":"Ann. Oncol."},{"key":"4030_CR20","doi-asserted-by":"publisher","unstructured":"Cremolini, C. et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.20.01225 (2020).","DOI":"10.1200\/JCO.20.01225"},{"key":"4030_CR21","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3389\/fonc.2020.00586","volume":"10","author":"Y Guan","year":"2020","unstructured":"Guan, Y. et al. FOLFOX chemotherapy ameliorates CD8 T lymphocyte exhaustion and enhances checkpoint blockade efficacy in colorectal cancer. Front. Oncol. 10, 586 (2020).","journal-title":"Front. Oncol."},{"key":"4030_CR22","first-page":"891","volume":"3","author":"E Gamelin","year":"1997","unstructured":"Gamelin, E. et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin. Cancer Res. 3, 891\u2013899 (1997).","journal-title":"Clin. Cancer Res."},{"key":"4030_CR23","doi-asserted-by":"publisher","first-page":"CT131","DOI":"10.1158\/1538-7445.AM2025-CT131","volume":"85","author":"H Bando","year":"2025","unstructured":"Bando, H. et al. Abstract CT131: A randomized, double-blind, phase III study comparing trifluridine\/tipiracil (FTD\/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): the ALTAIR study. Cancer Res. 85, CT131 (2025).","journal-title":"Cancer Res."},{"key":"4030_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1200\/JCO.2024.42.3_suppl.148","volume":"42","author":"L Pappas","year":"2024","unstructured":"Pappas, L. et al. Early identification and treatment of occult metastatic disease in stage III colon cancer (SU2C ACT3 clinical trial). J. Clin. Oncol. 42, 148 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4030_CR25","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/s41587-021-00900-z","volume":"39","author":"JD Cohen","year":"2021","unstructured":"Cohen, J. D. et al. Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. Nat. Biotechnol. 39, 1220\u20131227 (2021).","journal-title":"Nat. Biotechnol."},{"key":"4030_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A. et al. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377\u2013381 (2009).","journal-title":"J. Biomed. Inform."},{"key":"4030_CR27","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).","journal-title":"J. Biomed. Inform."},{"key":"4030_CR28","doi-asserted-by":"crossref","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 3 (2011).","DOI":"10.14806\/ej.17.1.200"},{"key":"4030_CR29","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2212Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"4030_CR30","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1158\/2159-8290.CD-25-0375","volume":"15","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Detection of cancers three years prior to diagnosis using plasma cell-free DNA. Cancer Discov. 15, 1794\u20131802 (2025).","journal-title":"Cancer Discov."},{"key":"4030_CR31","doi-asserted-by":"publisher","first-page":"9530","DOI":"10.1073\/pnas.1105422108","volume":"108","author":"I Kinde","year":"2011","unstructured":"Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W. & Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl Acad. Sci. USA 108, 9530\u20139535 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4030_CR32","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","volume":"33","author":"T Andre","year":"2015","unstructured":"Andre, T. et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J. Clin. Oncol. 33, 4176\u20134187 (2015).","journal-title":"J. Clin. Oncol."},{"key":"4030_CR33","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","volume":"29","author":"G Yothers","year":"2011","unstructured":"Yothers, G. et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J. Clin. Oncol. 29, 3768\u20133774 (2011).","journal-title":"J. Clin. Oncol."},{"key":"4030_CR34","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","volume":"30","author":"RJ Motzer","year":"2012","unstructured":"Motzer, R. J. et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J. Clin. Oncol. 30, 1371\u20131377 (2012).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04030-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04030-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04030-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:59:40Z","timestamp":1765814380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04030-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4030"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04030-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.T. has served as an advisor\/consultant for Haystack Oncology, Amgen, Novartis, AstraZeneca, Merck Serono, Merck Sharp & Dohme, BeiGene, Pierre Fabre, Bristol Myers Squibb, Gilead, Roche, Takeda and Daiichi-Sankyo and reports funding to their institution from Pfizer, Roche, Grail, Pierre Fabre, Daiichi-Sankyo, Zentalis, AstraZeneca and GlaxoSmithKline. Y.W. is a consultant to Belay Diagnostics and Haystack Oncology. J.L. consults for Taiho, Ipsen, Pfizer, Amgen, Merck, GlaxoSmithKline and Novartis and received research funding from Ipsen, Amgen, AstraZeneca, Foundation Medicine, Bayer, Personalis Inc., Guardant and Agenus. B.V. and K.W.K. are founders of Exact Sciences. K.W.K. and N.P. are advisors to, and hold equity in, Exact Sciences. B.V., K.W.K. and N.P. are founders of, and hold equity in, Clasp Therapeutics and Haystack Oncology, a Quest Diagnostics company. K.W.K., B.V. and N.P. are consultants to, and hold equity in, CAGE Pharma. B.V. is a consultant to, and holds equity in, Catalio Capital Management. C.B. is a consultant to Depuy-Synthes, Bionaut Labs, Haystack Oncology and Galectin Therapeutics. C.B. is also a co-founder of OrisDx and a co-founder of Belay Diagnostics. M.P. is a consultant to Haystack Oncology. L.D. is an employee of Haystack Oncology. The companies named above, as well as other companies, have licensed previously described technologies related to the work described in this paper from Johns Hopkins University. B.V., K.W.K., N.P. and C.B. are inventors on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. Patent applications on the work described in this paper may be filed by Johns Hopkins University. The terms of all these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies. D.B. has received honoraria for consultancies from AstraZeneca, Janssen, BeiGene, Boehringer Ingelheim, Bayer, Guardant Health and Amgen and speaking fees from Merck, AstraZeneca and Roche. P.G. is a consultant to Haystack Oncology. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}